ContraFect (CFRX) Stock Price, News & Analysis

Company Overview

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Key Stats

• Today's Range: $0.05 to $0.06
• 50-Day Range: $0.05 to $0.07
• 52-Week Range: $0.04 to $13.02
• Volume: 910,216 shs
• Average Volume: 1.39 million shs
• Market Capitalization: $535 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CFRX Stock Analysis - Frequently Asked Questions

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) EPS for the quarter, beating analysts' consensus estimates of ($22.64) by $12.24.

When did ContraFect's stock split?

ContraFect shares reverse split on the morning of Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Meta Platforms (META), Tonix Pharmaceuticals (TNXP), Novavax (NVAX), VBI Vaccines (VBIV) and Cidara Therapeutics (CDTX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 6/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CFRX
• CIK: 1478069
• Web: www.contrafect.com
• Phone: (914) 207-2300
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($19.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -138.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.53
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($19.92) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 10,700,000
• Free Float: 10,639,000
• Market Cap: $535 thousand
• Optionable: Not Optionable
• Beta: 0.29